Latest / The Well-Built Life / Metformin
Transcript
- 0:00Speaker 1: Hey everyone, welcome back to The Well-Built Life. I am
- 0:03Speaker 1: Rachel Caldwell, alongside Thomas Bennett, and we are so glad
- 0:07Speaker 1: you are tuning in. We are here to cut through
- 0:10Speaker 1: the noise, skip the intense jargon and extreme rules, and
- 0:14Speaker 1: share simple, practical habits that help you feel stronger, healthier,
- 0:18Speaker 1: and more balanced every single day. Grab a drink, get comfortable,
- 0:23Speaker 1: and let's dive in. Let's dive into the fascinating journey
- 0:26Speaker 1: of metformin. a medication that's been changing the landscape of
- 0:30Speaker 1: diabetes management since the 1950s. It all started in France,
- 0:36Speaker 1: where researchers first noticed its unique properties.
- 0:38Speaker 2: Exactly. It's a testament to how innovative research in the
- 0:42Speaker 2: early days laid the groundwork for what we have today.
- 0:46Speaker 2: Who would have thought that a simple molecule could have
- 0:48Speaker 2: such a profound impact on chronic disease management?
- 0:51Speaker 1: Right. It was initially used for non-insulin-dependent diabetes. but its
- 0:57Speaker 1: effectiveness soon caught the attention of the global health community.
- 1:01Speaker 1: By the 1970s, it was already approved in several countries.
- 1:07Speaker 1: But it wasn't until the mid-1990s that the UK prospective
- 1:12Speaker 1: diabetes study really cemented its place as a cornerstone in
- 1:16Speaker 1: diabetes management.
- 1:17Speaker 2: That was indeed a landmark study. It demonstrated that metformin
- 1:22Speaker 2: not only controlled blood sugar levels, but also reduced the
- 1:25Speaker 2: risk of complications and mortality among overweight individuals with newly
- 1:29Speaker 2: diagnosed type 2 diabetes, this finding really solidified its position
- 1:34Speaker 2: as the first-line drug for new cases.
- 1:37Speaker 1: Absolutely. The UKPDs showed a 37% reduction in the risk
- 1:42Speaker 1: of developing macrovascular complications over a 10-year follow-up period. But
- 1:47Speaker 1: the benefits don't stop there. Metformin has also been shown
- 1:51Speaker 1: to have a positive impact on cardiovascular health and weight management.
- 1:56Speaker 2: Right, the STOP, NIDNAM trial in 2006 was particularly eye-opening.
- 2:02Speaker 2: It looked at the long-term effects of metformin in reducing
- 2:05Speaker 2: the progression of heart disease and stroke. The results were impressive,
- 2:09Speaker 2: showing that metformin can indeed extend beyond just managing blood
- 2:13Speaker 2: sugar levels.
- 2:13Speaker 1: That's a shift we have seen over the years, moving
- 2:16Speaker 1: away from treating symptoms to addressing the root causes of
- 2:19Speaker 1: chronic conditions. but one must also consider the side effects
- 2:23Speaker 1: and monitoring needs. The UKPDs highlighted that up to 60%
- 2:28Speaker 1: of patients experienced gastrointestinal side effects during the first four
- 2:33Speaker 1: weeks of treatment.
- 2:34Speaker 2: True. Starting on a low dose and titrating gradually can
- 2:37Speaker 2: help manage those side effects. It's also important to monitor
- 2:41Speaker 2: vitamin B12 levels and kidney function, as both can be
- 2:45Speaker 2: affected by prolonged use. But despite these challenges … the
- 2:49Speaker 2: benefits often outweigh the side effects.
- 2:51Speaker 1: Correct. The diverse clinical responses to Metformin highlight the complexity
- 2:56Speaker 1: of its effects. While some patients see significant improvements, others
- 3:01Speaker 1: might not experience the same level of benefit. This has
- 3:05Speaker 1: sparked debates about its efficacy and application in different populations.
- 3:09Speaker 2: Exactly. To raise still a lot we don't fully understand
- 3:13Speaker 2: about its mechanisms. particularly its anti-inflammatory and anti-aging properties. These
- 3:20Speaker 2: areas are rich for future research, potentially uncovering new applications
- 3:24Speaker 2: beyond diabetes management.
- 3:26Speaker 1: And, as we look into the future, studies are ongoing
- 3:30Speaker 1: to explore metformin's role in preventing and treating complications like
- 3:34Speaker 1: nephropathy and neuropathy. Personalized dosing models and genetic testing might
- 3:40Speaker 1: also enhance its efficacy and safety. addressing the heterogeneity of
- 3:45Speaker 1: patient responses.
- 3:46Speaker 2: Absolutely. Metformin's future in healthcare is promising, offering a balance
- 3:51Speaker 2: of benefits and safety concerns. As research continues, we may
- 3:56Speaker 2: discover even more about its potential impacts on overall health
- 4:00Speaker 2: and wellness.
- 4:01Speaker 1: Let's dive into the detailed mechanisms of metformin and how
- 4:05Speaker 1: it works on a cellular level, starting with its impact
- 4:08Speaker 1: on glucose regulation. How does it manage to reduce the
- 4:11Speaker 1: amount of glucose released by the liver?
- 4:14Speaker 2: Well, it's fascinating. Metformin works primarily by inhibiting hepatic glucose production.
- 4:20Speaker 2: It targets enzymes involved in gluconeogenesis and glycogenolysis, reducing the
- 4:26Speaker 2: liver's contribution to postprandial hyperglycemia. Essentially, it's like a traffic
- 4:31Speaker 2: signal at a busy intersection. telling the liver to slow
- 4:34Speaker 2: down on glucose production.
- 4:36Speaker 1: And this is critical, especially since the liver can be
- 4:39Speaker 1: a significant source of glucose. But how does it affect
- 4:42Speaker 1: insulin sensitivity? I mean, it sounds so straightforward, but the
- 4:48Speaker 1: mechanisms are actually quite intricate.
- 4:50Speaker 2: Exactly. Metformin enhances insulin signaling in peripheral tissues. It's as
- 4:56Speaker 2: if insulin has a harder time unlocking doors to cells,
- 4:59Speaker 2: and metformin gives it a key. Research shows that it
- 5:03Speaker 2: activates AMP-activated protein kinase, AMP-Key, which is like a cellular
- 5:07Speaker 2: fuel gauge. When glucose levels are high, AMP-Key gets activated,
- 5:12Speaker 2: promoting insulin sensitivity and glucose uptake in muscle and adipose tissues.
- 5:17Speaker 1: That's a clever way to explain it. And what about
- 5:20Speaker 1: the UK Prospective Diabetes Study, UKPDs? What does it tell
- 5:25Speaker 1: us about metformin's impact on glucose regulation and overall health?
- 5:30Speaker 2: The UKPDs is a game-zand-changer. It followed over Senzen Pasaka
- 5:34Speaker 2: participants for sure years and showed that metformin significantly reduced
- 5:39Speaker 2: the risk of macrovascular complications by Bifengers-Sashutsi, a substantial finding.
- 5:44Speaker 2: The study's long-zand-term nature gives us confidence in its sustained
- 5:48Speaker 2: benefits and suggests that metformin lowers hemoglobin Aussie levels. and
- 5:53Speaker 2: improves overall glycemic control.
- 5:56Speaker 1: And speaking of practical takeaways, the UKPDs also highlighted metformin's
- 6:01Speaker 1: role in weight loss. Can you elaborate on that?
- 6:04Speaker 2: Sure. The study found that participants who took metformin had
- 6:08Speaker 2: a modest weight loss of about 3.5 kilograms on average.
- 6:12Speaker 2: This might be linked to improved insulin sensitivity and reduced
- 6:16Speaker 2: hepatic glucose output, leading to less energy production and storage.
- 6:20Speaker 2: It's not just a side effect, but a potential benefit,
- 6:23Speaker 2: especially for those with comorbid obesity.
- 6:26Speaker 1: That's interesting. So, does this mean that weight loss should
- 6:30Speaker 1: always be attributed to metformin? Or are there other factors
- 6:34Speaker 1: at play?
- 6:34Speaker 2: That's a great question. While metformin can contribute to weight loss,
- 6:38Speaker 2: it's often not the only factor. Many participants in the
- 6:42Speaker 2: UKPDs also made lifestyle changes, such as diet and exercise,
- 6:47Speaker 2: which can further enhance weight loss. So, while metformin may help,
- 6:51Speaker 2: Its primary role is in managing blood sugar, and any
- 6:54Speaker 2: weight loss is likely a secondary effect.
- 6:56Speaker 1: That makes sense. And we should always be cautious about
- 7:00Speaker 1: over-claiming its effects. Moving on, what about the potential side
- 7:05Speaker 1: effects and monitoring needs? How do they fit into the
- 7:08Speaker 1: overall picture of metformin's use?
- 7:10Speaker 2: Gastrointestinal side effects are a common concern, affecting up to
- 7:14Speaker 2: 60% of patients within the first four weeks. Proper management.
- 7:19Speaker 2: such as starting with a low dose and gradually increasing it,
- 7:22Speaker 2: can help mitigate these. Additionally, long-term use requires monitoring of
- 7:28Speaker 2: vitamin B12 levels and kidney function. Ensuring these are checked
- 7:32Speaker 2: can prevent more serious adverse events associated with lactic acidosis,
- 7:37Speaker 2: although the risk is generally low.
- 7:39Speaker 1: All of this information is incredibly insightful. It really underscores
- 7:44Speaker 1: the complex yet effective nature of metformin. What's the future
- 7:48Speaker 1: of metformin beyond managing blood sugar? Can it have broader
- 7:53Speaker 1: applications in chronic disease management or even longevity?
- 7:57Speaker 2: It's an intriguing possibility. Ongoing research is exploring metformin's potential
- 8:02Speaker 2: anti-inflammatory and anti-aging effects. The UKPDs and other studies suggest
- 8:07Speaker 2: benefits beyond diabetes. hinting at its role in cancer prevention
- 8:12Speaker 2: and cardiovascular health. Personalized dosing models and genetic testing might
- 8:16Speaker 2: also enhance its effectiveness, addressing individual differences in response to
- 8:21Speaker 2: the drug.
- 8:22Speaker 1: Looking forward, metformin certainly has a lot to offer beyond
- 8:25Speaker 1: diabetes management. It's fascinating to see how its mechanisms are
- 8:30Speaker 1: being uncovered and how they could lead to broader therapeutic applications. So,
- 8:35Speaker 1: let's dive into the cardiovascular benefits of metformin. The UKPD
- 8:40Speaker 1: study found a reduction in the risk of major cardiovascular
- 8:43Speaker 1: events by 31%, which is pretty significant, but to raise
- 8:47Speaker 1: more to the story than just numbers. What do you think, Thomas?
- 8:52Speaker 1: What's behind this reduction in cardiovascular risk?
- 8:55Speaker 2: It's interesting you mention that, Rachel. The UKPD's data suggests
- 8:59Speaker 2: a decrease in both macrovascular and microvascular complications, which isn't
- 9:04Speaker 2: limited to just glucose control. Metformin seems to be influencing
- 9:09Speaker 2: multiple pathways. For instance, it has anti-inflammatory effects and can
- 9:14Speaker 2: improve endothelial function, which could play a role in cardiovascular health. Right.
- 9:19Speaker 1: And that's the crucial nuance here. It's not just about
- 9:22Speaker 1: blood sugar levels. It's about the intricate way the drug
- 9:25Speaker 1: interacts with the body. Can you elaborate on how metformin
- 9:29Speaker 1: might improve endothelial function and reduce inflammation?
- 9:33Speaker 2: Of course. Metformin can activate AMP-activated protein kinase AMP, which
- 9:38Speaker 2: is kind of like a cellular energy sensor, activating AMP
- 9:41Speaker 2: kelps and reducing fatty acid oxidation and inflammation, which can
- 9:46Speaker 2: affect endothelial cells. This dual action on reducing inflammation and
- 9:51Speaker 2: improving energy metabolism could be key.
- 9:53Speaker 1: That's wild when you look at the raw numbers. But
- 9:56Speaker 1: what about the side effects? The UKPDs also noted that
- 10:00Speaker 1: up to 60% of patients might experience gastrointestinal discomfort. Have
- 10:04Speaker 1: there been efforts to address these issues and improve patient compliance?
- 10:08Speaker 2: Absolutely, Rachel. One strategy is to start with a lower
- 10:12Speaker 2: dose and gradually titrate up to the maintenance dose. This
- 10:16Speaker 2: approach can help manage side effects like diarrhea and abdominal discomfort. Also,
- 10:22Speaker 2: monitoring vitamin B12 levels and kidney function is crucial, as
- 10:26Speaker 2: depletion of B12 can lead to anemia, and changes in
- 10:30Speaker 2: renal function can affect drug clearance.
- 10:32Speaker 1: Exactly, which brings up an interesting contradiction. While metformin is
- 10:37Speaker 1: a first-line treatment for diabetes, some studies show that it
- 10:41Speaker 1: might be less effective in overweight individuals. How do we
- 10:45Speaker 1: navigate this when advising patients?
- 10:47Speaker 2: Great question. It's a complex issue. While metformin does work
- 10:51Speaker 2: well in many, it doesn't work equally as well in everyone,
- 10:54Speaker 2: especially those with more severe obesity. This highlights the need
- 10:58Speaker 2: for personalized approaches, such as genetic testing, to identify responders
- 11:03Speaker 2: and non-responders.
- 11:04Speaker 1: Personalized dosing and genetic testing. That's a potential game changer.
- 11:09Speaker 1: But it also adds an extra layer of complexity for
- 11:11Speaker 1: patients and healthcare providers. In the meantime, how do we
- 11:15Speaker 1: ensure that Metformin's broader benefits are reaching enough people, particularly
- 11:19Speaker 1: in areas with limited healthcare resources?
- 11:22Speaker 2: That's a good point. Access and affordability are key. Integrating
- 11:26Speaker 2: Metformin into primary care and public health programs can help.
- 11:30Speaker 2: Governments and NGOs can play a role in providing affordable
- 11:34Speaker 2: access and educating the public on the drug's benefits. Tailoring
- 11:38Speaker 2: educational materials to different demographics can also increase awareness and acceptance. True.
- 11:43Speaker 1: And it's not just about giving the drug, it's about
- 11:46Speaker 1: ensuring patients know how to use it effectively. Speaking of which,
- 11:51Speaker 1: what do you think about the potential of metformin for
- 11:53Speaker 1: non-diabetic populations looking to manage chronic conditions? Are we seeing
- 11:59Speaker 1: enough interest and research in this area?
- 12:01Speaker 2: The interest is growing and to raise a lot of
- 12:04Speaker 2: ongoing research. Metformin's anti-inflammatory and anti-aging properties raise the possibility
- 12:10Speaker 2: of using it for conditions like metabolic syndrome, polycystic ovary syndrome,
- 12:15Speaker 2: and even certain types of cancer. But more studies are
- 12:18Speaker 2: needed to fully explore these potential applications.
- 12:22Speaker 1: Absolutely. And that's where the future lies combining metformin's proven
- 12:26Speaker 1: benefits with new avenues of research. It's a promising area
- 12:30Speaker 1: that could revolutionize chronic disease management. Thanks for diving deep
- 12:34Speaker 1: into these nuances. Thomas.
- 12:36Speaker 2: Anytime, Rachel. It's clear that metformin is more than just
- 12:40Speaker 2: a diabetes drug. It's a multifaceted player in the realm
- 12:43Speaker 2: of chronic disease management. We just need to explore its
- 12:47Speaker 2: full potential.
- 12:48Speaker 1: So, let's delve into the debate around metformin's weight loss claims.
- 12:53Speaker 1: It's interesting to note that in clinical trials, metformin can
- 12:56Speaker 1: lead to modest weight loss, but the mechanisms behind this
- 13:00Speaker 1: aren't entirely clear. What do you think, Thomas? Could the
- 13:04Speaker 1: improvements in blood sugar control somehow correlate with weight loss?
- 13:09Speaker 2: Exactly, because that's a key point. The UKPDs found that
- 13:13Speaker 2: metformin helped participants lose around 3.5 kilograms, which is a
- 13:18Speaker 2: significant improvement, but it might not be directly related to
- 13:21Speaker 2: the drug itself. More likely, it's about the lifestyle changes
- 13:26Speaker 2: people make when prescribed metformin. It's like telling someone to
- 13:29Speaker 2: eat healthier and exercise more, which can lead to weight loss.
- 13:33Speaker 2: But is it the metformin doing the job, or are
- 13:36Speaker 2: people eating better and moving more because of their diabetes management?
- 13:40Speaker 1: That's right. To resolve the argument that metformin's impact on
- 13:43Speaker 1: weight is just an added bonus. It's not the primary goal,
- 13:47Speaker 1: but it certainly can support weight management efforts. Moving on,
- 13:52Speaker 1: there is some debate about the risk of lactic acidosis.
- 13:55Speaker 1: How big a concern is this really, and how do
- 13:57Speaker 1: we balance the clinical utility against the need to monitor
- 14:01Speaker 1: this risk?
- 14:02Speaker 2: It's a cautious one. While the risk of lactic acidosis
- 14:05Speaker 2: is generally low, it can be severe when it does happen.
- 14:09Speaker 2: The debate is about whether the benefits of metformin outweigh
- 14:11Speaker 2: this risk, especially considering that the condition is rare. One
- 14:15Speaker 2: way to approach this is through more precise monitoring and
- 14:19Speaker 2: education for patients, ensuring they understand the signs of lactic
- 14:23Speaker 2: acidosis and know when to seek medical help. It's not
- 14:27Speaker 2: an uncommon issue, but definitely something to keep in mind.
- 14:30Speaker 1: True, the monitoring can be key. Speaking of which, the
- 14:34Speaker 1: variability in how metformin affects different individuals is fascinating. Some
- 14:40Speaker 1: patients see huge improvements in their glycemic control while others
- 14:44Speaker 1: don't experience much change. This heterogeneity challenges the idea that
- 14:49Speaker 1: it's a one size fits all solution. How might personalization
- 14:54Speaker 1: impact the situation?
- 14:55Speaker 2: That's a great question. Personalization could definitely help. For instance,
- 15:00Speaker 2: genetic testing might reveal why some people respond better than others.
- 15:05Speaker 2: This could lead to a more tailored approach. adjusting dosing
- 15:09Speaker 2: or using metformin in combination with other drugs, the goal
- 15:13Speaker 2: is to maximize the benefits while minimizing potential side effects. However,
- 15:18Speaker 2: we are still in the early stages of understanding how
- 15:21Speaker 2: genetics play into it.
- 15:23Speaker 1: And let's not forget the comparison with newer therapies. Metformin
- 15:27Speaker 1: has been around a long time, and newer drugs with
- 15:31Speaker 1: potentially better efficacy and fewer side effects are emerging. This
- 15:35Speaker 1: comparison is is crucial in deciding where metformin stands in
- 15:39Speaker 1: the therapeutic landscape. How do you see that playing out?
- 15:44Speaker 2: The competition from newer drugs is a valid critique. They
- 15:47Speaker 2: are often touted as more advanced with fewer side effects
- 15:51Speaker 2: and better outcomes. But we must remember that metformin has
- 15:55Speaker 2: many years of proven effectiveness and is more accessible and affordable.
- 15:59Speaker 2: The debate is about finding the most effective and safe
- 16:02Speaker 2: combination of treatments for different patients. We need comprehensive studies
- 16:07Speaker 2: to compare these directly and understand the best practices moving forward.
- 16:11Speaker 1: Absolutely. And with ongoing research, we might discover new applications
- 16:16Speaker 1: for metformin, expanding its use beyond diabetes into areas like
- 16:20Speaker 1: heart health and even cancer prevention. It's exciting to think
- 16:23Speaker 1: about where this could lead, but we need more data
- 16:26Speaker 1: to support these ideas. What do you think are some
- 16:29Speaker 1: key areas for future research?
- 16:31Speaker 2: The exact mechanisms of metformin's non-glycemic effects are a big area.
- 16:37Speaker 2: We need to understand more about its anti-inflammatory and anti-aging properties,
- 16:42Speaker 2: which could open up new avenues for treatment. Personalized medicine,
- 16:47Speaker 2: as you mentioned, is crucial. And more long-term studies to
- 16:50Speaker 2: evaluate the long-term side effects and benefits would be invaluable.
- 16:55Speaker 2: It's a complex interplay, but the potential benefits are significant. Right.
- 16:59Speaker 1: Let's shift gears a bit. Metformin has shown promise not
- 17:03Speaker 1: just in managing diabetes, but also in anti-inflammatory and anti-aging benefits.
- 17:09Speaker 1: What do you think are the biggest unanswered questions in
- 17:12Speaker 1: this area?
- 17:12Speaker 2: Exactly. Because while the initial findings are promising, we need
- 17:16Speaker 2: to understand the exact mechanisms and how it interacts with
- 17:21Speaker 2: other biological processes. For instance, Do you think the anti-inflammatory
- 17:26Speaker 2: effects come from a direct action on immune cells, or
- 17:29Speaker 2: is it more about signaling pathways being affected?
- 17:32Speaker 1: That's a great point. The inflammatory response is quite complex,
- 17:36Speaker 1: and metformin could be modulating multiple pathways. It's interesting to
- 17:41Speaker 1: see how it might be involved in reducing the production
- 17:44Speaker 1: of pro-inflammatory cytokines. But the exact signaling cascade is still murky.
- 17:51Speaker 2: And what about its role in aging? I have seen
- 17:54Speaker 2: some studies suggesting metformin can extend lifespan in animals, but
- 17:58Speaker 2: the mechanisms are still a bit of a mystery. Perhaps
- 18:01Speaker 2: it's through its effects on mitochondrial function, or maybe it's
- 18:05Speaker 2: influencing epigenetic factors.
- 18:07Speaker 1: Right, and that's the crucial nuance here. Mitochondrial health is
- 18:11Speaker 1: definitely one area of interest, as aging and cellular damage
- 18:15Speaker 1: are closely tied. The question is, can these findings be
- 18:19Speaker 1: translated into human health benefits? And if so, how would
- 18:22Speaker 1: we implement such insights in clinical practice?
- 18:26Speaker 2: That's a million-dollar question. It's not as straightforward as just
- 18:30Speaker 2: prescribing the same dose for everyone, given the variable responses
- 18:33Speaker 2: we see. Personalized medicine could be the key, perhaps using
- 18:38Speaker 2: genetic testing to tailor dosing to an individual's profile, or
- 18:42Speaker 2: perhaps combining metformin with other therapies to enhance its efficacy.
- 18:46Speaker 1: Exactly. Which brings up an interesting contradiction. While metformin seems
- 18:51Speaker 1: to have broad benefits, its side effects, such as gastrointestinal issues,
- 18:55Speaker 1: are still concerning. How can we balance the benefits with
- 18:59Speaker 1: the downsides, especially in a personalized approach?
- 19:02Speaker 2: True. Addressing the side effects might involve more careful initial
- 19:07Speaker 2: administration using start-low, go-slow strategies. Kidney function is also a
- 19:13Speaker 2: critical concern, so ongoing monitoring would be necessary. But if
- 19:17Speaker 2: we can develop better ways to manage these, Metformin could
- 19:21Speaker 2: truly be a game changer.
- 19:22Speaker 1: And how do you think this research will shape future
- 19:25Speaker 1: treatment strategies for diabetes and beyond? Do you see a
- 19:29Speaker 1: shift towards more integrated, multimodal approaches?
- 19:33Speaker 2: Definitely. The goal would be to use metformin as part
- 19:37Speaker 2: of a broader strategy that includes lifestyle changes, diet, and
- 19:41Speaker 2: other medications. Understanding the mechanisms better could lead to new
- 19:44Speaker 2: drugs or therapies that work synergistically with metformin to improve outcomes.
- 19:49Speaker 1: It's all about moving forward with a multifaceted approach. And
- 19:52Speaker 1: with all these unanswered questions, research is clearly still a
- 19:56Speaker 1: major player in shaping the future of diabetes and overall health.
- 20:01Speaker 1: What would you say are the key areas that need
- 20:04Speaker 1: the most attention next.
- 20:05Speaker 2: Key areas include understanding the exact molecular pathways involved, developing
- 20:11Speaker 2: personalized dosing strategies, and confirming the clinical relevance of these
- 20:16Speaker 2: findings in larger, more diverse populations. Plus, more research on
- 20:21Speaker 2: the long-term effects and interactions with other drugs.
- 20:24Speaker 1: Agreed. The journey ahead is full of possibilities, but it
- 20:28Speaker 1: will take a collaborative effort to realize them. Thanks for
- 20:32Speaker 1: the insights, and let's keep an eye on this exciting field.
- 20:35Speaker 1: That brings us to the end of today's episode. Thank
- 20:38Speaker 1: you so much for spending part of your day with me.
- 20:42Speaker 1: If you found this episode's tips helpful and want to
- 20:44Speaker 1: make sure you don't miss the next conversation, please take
- 20:48Speaker 1: a quick second to hit that subscribe or follow button
- 20:51Speaker 1: on whatever platform you are listening on. It's a completely
- 20:55Speaker 1: free way to support the show and helps more people
- 20:57Speaker 1: find us. This podcast is independently produced. So if you
- 21:01Speaker 1: are ever in a position where you would like to
- 21:03Speaker 1: help keep it running, we do accept small donations. You
- 21:07Speaker 1: can find a link right in the episode description below.
- 21:09Speaker 1: To buy us a coffee or contribute what you can,
- 21:12Speaker 1: every bit genuinely helps. Take care of yourself, stay balanced,
- 21:17Speaker 1: and we will talk again soon.